Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from David Bautz

ATE.TO: Plans on Track for Acute Pain Program for Otenaproxesul…

By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT

Benzinga

VIVXF: OxC-beta Approved in China…

By David Bautz, PhD MKT:TICKER READ THE FULL VIVXF RESEARCH REPORT

Benzinga

QLGN: FastPack Sales Up 28% YoY…

By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

BTAI: SERENITY III Trial to Initiate in 2H22…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga

ARWR: Phase 1/2a Clinical Trials Underway for Pulmonary Disease Candidates…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Benzinga

CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility…

Bautz: By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

APLIF: New Late Stage Program to Treat Cutaneous Leishmaniasis…

Bautz: By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT

Benzinga

EPIX: Encouraging Signs of Activity in Phase 1 Trial of EPI-7386…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga

ATE.TO: Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22…

By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT

Benzinga

MDNA: Encouraging CD8+ T Cell and NK Cell Responses in ABILITY Trial…

By David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT

Benzinga

BVXV: Significant Progress Made in NanoAb Program…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

Benzinga

SNGX: Bivalent Filovirus Vaccine Candidate Provides 100% Protection in Non-Human Primates…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Benzinga

MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

CLSN: OVATION 2 Study 85% Enrolled…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Benzinga

EPIX: Clinical Update on Phase 1 Monotherapy Trial of EPI-7386 Expected in 2Q22…

By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT

Benzinga

CFRX: Results from Interim Futility Analysis in July 2022…

By David Bautz, PhD NASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT

Benzinga

DFFN: Data from Altitude Trial Expected in June 2022…

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

BCLI: Anticipating News on How NurOwn® Will be Advanced Forward…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT

Benzinga

EDSA: Enrollment of Phase 2b Trial of EB01 to Complete in 4Q22…

By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT

Benzinga

SNGX: Phase 2a Trial of SGX302 in Psoriasis to Initiate in Second Half of 2022…

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT

Benzinga

VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…

By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT

Benzinga

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

Benzinga

VIVXF: OxC-beta Approved in Vietnam…

By David Bautz, PhD OTC:VIVXF READ THE FULL VIVXF RESEARCH REPORT

Benzinga

BVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…

By David Bautz, PhD NASDAQ:BVXV READ THE FULL BVXV RESEARCH REPORT

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Department of Defense

178 stories

University College London

New England Journal of Medicine

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.